Maxim Group Downgrades Reviva Pharmaceuticals to Hold

Benzinga Newsdesk www.benzinga.com Negative 88.8%

Neg 88.8% Neu 0% Pos 0%

Maxim Group analyst Jason McCarthy downgrades Reviva Pharmaceuticals (NASDAQ:RVPH) from Buy to Hold.

Comments

No comments yet. Be the first!